FDA 483 - Lonza Biologics, Inc. - March 07, 2024
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Lonza Biologics, Inc. in Portsmouth, NH, a biological drug substance manufacturer, revealed two significant observations. The firm failed to adequately investigate unexplained discrepancies related to calibration data and incorrectly assessed failing data as passing. Additionally, the company did not follow its own established procedures for process descriptions, continuing manufacturing even after critical test failures were identified for bulk drug substances.
ID · a5417b6a-1ebe-4cd5-8ba7-eae412f0931f